Dynamic serological monitoring of COVID-19 vaccine response in immunocompromised populations

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results: S1 subunit of the spike protein Receptor Binding Domain (RBD) of the spike protein Nucleocapsid protein Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs. Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab. Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols. For Research Use Only.  Not for use in diagnostic procedures.